Literature DB >> 26308594

Monoclonal Antibodies in Multiple Myeloma Come of Age.

Noopur Raje1, Dan L Longo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26308594     DOI： 10.1056/NEJMe1509419

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

Review 1.  An update on the role of daratumumab in the treatment of multiple myeloma.

Authors:  Caitlin Costello
Journal:  Ther Adv Hematol       Date:  2016-11-24

2.  Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.

Authors:  Gang An; Chirag Acharya; Xiaoyan Feng; Kenneth Wen; Mike Zhong; Li Zhang; Nikhil C Munshi; Lugui Qiu; Yu-Tzu Tai; Kenneth C Anderson
Journal:  Blood       Date:  2016-07-14       Impact factor: 22.113

3.  A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma.

Authors:  Wing Keung Chan; Siwen Kang; Youssef Youssef; Erin N Glankler; Emma R Barrett; Alex M Carter; Elshafa H Ahmed; Aman Prasad; Luxi Chen; Jianying Zhang; Don M Benson; Michael A Caligiuri; Jianhua Yu
Journal:  Cancer Immunol Res       Date:  2018-05-16       Impact factor: 11.151

4.  A novel approach to remove interference of therapeutic monoclonal antibody with serum protein electrophoresis.

Authors:  Li Liu; Michael R Shurin; Sarah E Wheeler
Journal:  Clin Biochem       Date:  2019-11-11       Impact factor: 3.281

Review 5.  SLAMF6 in health and disease: Implications for therapeutic targeting.

Authors:  Burcu Yigit; Ninghai Wang; Roland W Herzog; Cox Terhorst
Journal:  Clin Immunol       Date:  2018-10-23       Impact factor: 3.969

6.  BAFF is involved in macrophage-induced bortezomib resistance in myeloma.

Authors:  Jing Chen; Donghua He; Qingxiao Chen; Xing Guo; Li Yang; Xuanru Lin; Yi Li; Wenjun Wu; Yang Yang; Jingsong He; Enfan Zhang; Qing Yi; Zhen Cai
Journal:  Cell Death Dis       Date:  2017-11-02       Impact factor: 8.469

7.  Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo.

Authors:  William Fumey; Julia Koenigsdorf; Valentin Kunick; Stephan Menzel; Kerstin Schütze; Mandy Unger; Levin Schriewer; Friedrich Haag; Gerhard Adam; Anna Oberle; Mascha Binder; Ralf Fliegert; Andreas Guse; Yong Juan Zhao; Hon Cheung Lee; Fabio Malavasi; Fernando Goldbaum; Rob van Hegelsom; Catelijne Stortelers; Peter Bannas; Friedrich Koch-Nolte
Journal:  Sci Rep       Date:  2017-10-30       Impact factor: 4.379

Review 8.  Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.

Authors:  Tiantian Zhang; Sen Wang; Tengfei Lin; Jingmei Xie; Lina Zhao; Zhuoru Liang; Yangqiu Li; Jie Jiang
Journal:  Oncotarget       Date:  2017-05-16

Review 9.  Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting.

Authors:  Kejie Zhang; Aakash Desai; Dongfeng Zeng; Tiejun Gong; Peihua Lu; Michael Wang
Journal:  Oncotarget       Date:  2017-02-07

10.  Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma.

Authors:  Haibo Sun; Thomas G Martin; John Marra; Denice Kong; Jonathon Keats; Sandrine Macé; Marielle Chiron; Jeffrey L Wolf; Jeffrey M Venstrom; Raja Rajalingam
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.